Identification

Name
Tizanidine
Accession Number
DB00697  (APRD00128)
Type
Small Molecule
Groups
Approved, Investigational
Description

Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.

Structure
Thumb
Synonyms
  • 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole
  • Tizanidin
  • Tizanidina
  • Tizanidine
  • Tizanidinum
External IDs
AN 021 / DS 103-282
Product Ingredients
IngredientUNIICASInChI Key
Tizanidine HydrochlorideB53E3NMY5C64461-82-1ZWUKMNZJRDGCTQ-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TizanidineTablet2 mgOralAa Pharma IncNot applicableNot applicableCanada
TizanidineTablet4 mgOralAa Pharma Inc2004-11-17Not applicableCanada
Tizanidine HydrochlorideCapsule, gelatin coated2 mg/1OralActavis Pharma Company2012-02-06Not applicableUs00591 2788 86 nlmimage10 873cc3b6
Tizanidine HydrochlorideCapsule, gelatin coated6 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2012-02-06Not applicableUs
Tizanidine HydrochlorideCapsule, gelatin coated6 mg/1OralActavis Pharma Company2012-02-06Not applicableUs
Tizanidine HydrochlorideCapsule, gelatin coated6 mg/1Oralbryant ranch prepack2012-02-06Not applicableUs
Tizanidine HydrochlorideCapsule, gelatin coated4 mg/1OralActavis Pharma Company2012-02-06Not applicableUs00591 2789 86 nlmimage10 903cc836
Tizanidine HydrochlorideCapsule, gelatin coated2 mg/1OralClinical Solutions Wholsesale2012-02-062017-06-23Us
ZanaflexCapsule2 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-28Not applicableUs
ZanaflexCapsule4 mg/1OralAcorda Therapeutics2005-04-04Not applicableUs10144 0604 15 nlmimage10 f21df94f
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Comfort Pac with TizanidineKitPd Rx Pharmaceuticals, Inc.2013-07-09Not applicableUs
Mylan-tizanidineTablet4 mgOralMylan Pharmaceuticals2006-02-162017-01-09Canada
Pal-tizanidineTablet4 mgOralPaladin Labs Inc1999-10-29Not applicableCanada
TizanidineTablet2 mg/1OralAidarex Pharmaceuticals LLC2002-07-03Not applicableUs
TizanidineTablet4 mg/1OralCardinal Health2002-07-032016-03-22Us
TizanidineTablet2 mg/1OralAphena Pharma Solutions Tennessee, Inc.2004-01-16Not applicableUs
TizanidineTablet4 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2013-04-01Not applicableUs
TizanidineTablet4 mg/1Oralbryant ranch prepack2004-01-16Not applicableUs
TizanidineTablet4 mg/1OralGolden State Medical Supply2004-01-16Not applicableUs
TizanidineTablet4 mg/1OralProficient Rx LP2004-01-16Not applicableUs
International/Other Brands
Cimbrar (Euroetika) / Musant (Actavis) / Myores (Meprofarm) / Navizan (Caber) / Relaxkov (Blaskov) / Sirdalid (Novartis) / Sirdalud (Novartis) / Sirdalud MR (Novartis) / Sizolan (Dr. Reddy's) / Spaslax (Panion & BF) / Telzanine (Nisshin Seiyaku) / Ternelin (Novartis) / Tizadin (ACL) / Tizaflex (Actavis) / Tizalud (Opsonin) / Tizan (Sun) / Zanpeak (Tatsumi Kagaku) / Zitanid (Novell)
Categories
UNII
6AI06C00GW
CAS number
51322-75-9
Weight
Average: 253.711
Monoisotopic: 253.018893678
Chemical Formula
C9H8ClN5S
InChI Key
XFYDIVBRZNQMJC-UHFFFAOYSA-N
InChI
InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)
IUPAC Name
5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
SMILES
ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1

Pharmacology

Indication

For the management of increased muscle tone associated with spasticity

Structured Indications
Pharmacodynamics

Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.

Mechanism of action

Tizanidine reduces spasticity by increasing presynaptic inhibition of motor neurons through agonist action at a2-adrenergic receptor sites.

TargetActionsOrganism
UAlpha-2A adrenergic receptor
agonist
Human
AAlpha-2B adrenergic receptor
agonist
Human
AAlpha-2C adrenergic receptor
agonist
Human
NNischarin
agonist
Human
Absorption
Not Available
Volume of distribution
  • 2.4 L/kg
Protein binding

30%

Metabolism
Route of elimination

Approximately 95% of an administered dose is metabolized.

Half life

2.5 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Tizanidine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Tizanidine can be increased when it is combined with Abiraterone.Approved
AcebutololTizanidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Aceprometazine.Approved
AciclovirThe serum concentration of Tizanidine can be increased when it is combined with Aciclovir.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Tizanidine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Alaproclate.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tizanidine.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tizanidine.Approved, Illicit
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Tizanidine is combined with Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tizanidine.Approved, Illicit, Investigational
AlprenololTizanidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Tizanidine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Tizanidine.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Tizanidine.Illicit, Withdrawn
AminophyllineThe serum concentration of Tizanidine can be increased when it is combined with Aminophylline.Approved
AmiodaroneThe serum concentration of Tizanidine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Tizanidine can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Tizanidine can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tizanidine.Approved, Illicit
AmoxapineAmoxapine may decrease the antihypertensive activities of Tizanidine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tizanidine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Tizanidine is combined with Amyl Nitrite.Approved
AnagrelideTizanidine may increase the QTc-prolonging activities of Anagrelide.Approved
AnastrozoleThe serum concentration of Tizanidine can be increased when it is combined with Anastrozole.Approved, Investigational
ApomorphineThe serum concentration of Tizanidine can be increased when it is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Tizanidine.Approved, Investigational
ArotinololTizanidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Investigational
Arsenic trioxideTizanidine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherTizanidine may increase the QTc-prolonging activities of Artemether.Approved
ArtenimolThe serum concentration of Tizanidine can be increased when it is combined with Artenimol.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Articaine.Approved
AsenapineTizanidine may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe serum concentration of Tizanidine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololTizanidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Azaperone.Investigational, Vet Approved
AzelastineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Tizanidine is combined with Azilsartan medoxomil.Approved, Investigational
AzithromycinThe serum concentration of Tizanidine can be increased when it is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Tizanidine.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Tizanidine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Tizanidine.Approved
BedaquilineTizanidine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololTizanidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Tizanidine.Approved
BenperidolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Tizanidine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineTizanidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Tizanidine.Approved, Withdrawn
BeractantTizanidine may increase the bradycardic activities of Beractant.Approved
BetaxololTizanidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Investigational
BevantololTizanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BisoprololTizanidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BopindololTizanidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe serum concentration of Tizanidine can be increased when it is combined with Bortezomib.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Tizanidine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tizanidine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tizanidine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Bromisoval.Experimental
BromocriptineThe serum concentration of Tizanidine can be increased when it is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololTizanidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolTizanidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Bumetanide.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Tizanidine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tizanidine.Approved, Investigational
BupranololTizanidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Tizanidine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tizanidine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tizanidine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Tizanidine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Tizanidine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tizanidine.Approved, Illicit, Vet Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Tizanidine.Approved
CaffeineThe serum concentration of Tizanidine can be increased when it is combined with Caffeine.Approved
CalfactantTizanidine may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Tizanidine is combined with Candesartan cilexetil.Approved
CandoxatrilThe risk or severity of hypotension can be increased when Tizanidine is combined with Candoxatril.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Tizanidine is combined with Canertinib.Investigational
CaptoprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tizanidine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tizanidine.Approved, Investigational
CarbimazoleThe serum concentration of Tizanidine can be increased when it is combined with Carbimazole.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Tizanidine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tizanidine.Approved
CarteololTizanidine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolTizanidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CeliprololTizanidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibTizanidine may increase the bradycardic activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tizanidine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tizanidine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Chloroprocaine.Approved
ChloroquineTizanidine may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorphenamine.Approved
ChlorpromazineTizanidine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Tizanidine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tizanidine.Approved
CilazaprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Tizanidine.Approved, Investigational
CimetidineThe serum concentration of Tizanidine can be increased when it is combined with Cimetidine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinTizanidine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideTizanidine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Tizanidine can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Tizanidine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Tizanidine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Tizanidine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Tizanidine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Tizanidine is combined with clomethiazole.Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Tizanidine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tizanidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clopenthixol.Experimental
CloranololTizanidine may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tizanidine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clothiapine.Experimental
ClotrimazoleThe serum concentration of Tizanidine can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Tizanidine can be increased when it is combined with Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tizanidine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Tizanidine.Approved, Investigational
Conjugated estrogensThe serum concentration of Tizanidine can be increased when it is combined with Conjugated estrogens.Approved
CrisaboroleThe serum concentration of Tizanidine can be increased when it is combined with Crisaborole.Approved, Investigational
CrizotinibTizanidine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Tizanidine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tizanidine.Approved
Cyproterone acetateThe serum concentration of Tizanidine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dantrolene.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dapoxetine.Investigational
DeferasiroxThe serum concentration of Tizanidine can be increased when it is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Delapril.Experimental
DelavirdineThe serum concentration of Tizanidine can be increased when it is combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tizanidine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Tizanidine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Tizanidine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tizanidine.Approved
DexmedetomidineThe serum concentration of Tizanidine can be increased when it is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tizanidine.Approved, Illicit, Investigational, Vet Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Tizanidine.Experimental
DiclofenacThe serum concentration of Tizanidine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Diclofenamide.Approved, Investigational
Diethyl etherThe risk or severity of adverse effects can be increased when Tizanidine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Difenoxin.Approved, Illicit
DigoxinDigoxin may increase the bradycardic activities of Tizanidine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tizanidine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Tizanidine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Tizanidine.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tizanidine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tizanidine.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dipyridamole.Approved
DisopyramideTizanidine may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe serum concentration of Tizanidine can be increased when it is combined with Disulfiram.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dixyrazine.Experimental
DofetilideTizanidine may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronTizanidine may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidoneTizanidine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilTizanidine may increase the bradycardic activities of Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Doramectin.Vet Approved
DosulepinThe serum concentration of Tizanidine can be increased when it is combined with Dosulepin.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Tizanidine.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Tizanidine.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Tizanidine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Tizanidine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved, Illicit
DronedaroneTizanidine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Drotebanol.Experimental, Illicit
DuloxetineTizanidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tizanidine.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Tizanidine.Approved, Investigational
EliglustatTizanidine may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of hypotension can be increased when Tizanidine is combined with Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe serum concentration of Tizanidine can be increased when it is combined with Entacapone.Approved, Investigational
EpanololTizanidine may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Tizanidine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Tizanidine is combined with Eprosartan.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Tizanidine.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Tizanidine.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Tizanidine.Approved
ErythromycinTizanidine may increase the QTc-prolonging activities of Erythromycin.Approved, Investigational, Vet Approved
EscitalopramTizanidine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Tizanidine.Investigational
EsmololTizanidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tizanidine.Approved, Illicit
EstradiolThe serum concentration of Tizanidine can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Tizanidine can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Tizanidine can be increased when it is combined with Estradiol benzoate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Tizanidine can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Tizanidine can be increased when it is combined with Estradiol dienanthate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Tizanidine can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tizanidine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etacrynic acid.Approved, Investigational
EthanolTizanidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tizanidine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Tizanidine.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tizanidine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fexofenadine.Approved, Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tizanidine.Approved, Investigational
FingolimodTizanidine may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlecainideTizanidine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fluanisone.Experimental
FluconazoleThe serum concentration of Tizanidine can be increased when it is combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe serum concentration of Tizanidine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolTizanidine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Tizanidine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tizanidine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fluspirilene.Approved, Investigational
FlutamideThe serum concentration of Tizanidine can be increased when it is combined with Flutamide.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Tizanidine.Approved
FluvastatinThe serum concentration of Tizanidine can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Tizanidine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fospropofol.Approved, Illicit, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Tizanidine.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tizanidine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Tizanidine is combined with Gabapentin Enacarbil.Approved, Investigational
Gadobenic acidTizanidine may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Tizanidine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tizanidine.Approved, Illicit, Investigational
GemifloxacinTizanidine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Tizanidine is combined with Gepirone.Investigational
GlecaprevirThe serum concentration of Tizanidine can be increased when it is combined with Glecaprevir.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Glutethimide.Approved, Illicit
Glycerol PhenylbutyrateThe serum concentration of Tizanidine can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GoserelinTizanidine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronTizanidine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolTizanidine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tizanidine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Hexobarbital.Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Tizanidine.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneTizanidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Tizanidine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tizanidine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
IbutilideTizanidine may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneTizanidine may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Tizanidine.Approved, Investigational
ImidaprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Imidapril.Investigational
ImipramineThe serum concentration of Tizanidine can be increased when it is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Indapamide.Approved
IndenololTizanidine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Tizanidine is combined with Indiplon.Investigational
IndoraminIndoramin may decrease the vasoconstricting activities of Tizanidine.Withdrawn
Interferon Alfa-2b, RecombinantThe serum concentration of Tizanidine can be increased when it is combined with Interferon Alfa-2b, Recombinant.Approved
Interferon gamma-1bThe serum concentration of Tizanidine can be increased when it is combined with Interferon gamma-1b.Approved, Investigational
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Tizanidine.Approved, Investigational
IprindoleIprindole may decrease the antihypertensive activities of Tizanidine.Experimental
IrbesartanThe risk or severity of adverse effects can be increased when Tizanidine is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tizanidine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tizanidine.Approved, Vet Approved
IsoniazidThe serum concentration of Tizanidine can be increased when it is combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Tizanidine.Approved, Investigational
IvabradineTizanidine may increase the bradycardic activities of Ivabradine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tizanidine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Tizanidine can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolTizanidine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineTizanidine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideTizanidine may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tizanidine.Approved, Investigational
LandiololTizanidine may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LanreotideTizanidine may increase the bradycardic activities of Lanreotide.Approved
LenvatinibTizanidine may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Tizanidine.Approved, Investigational
LeuprolideTizanidine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tizanidine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levocetirizine.Approved
LevodopaTizanidine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinTizanidine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Tizanidine.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tizanidine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Tizanidine.Approved, Investigational
LidocaineThe serum concentration of Tizanidine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LisinoprilTizanidine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Tizanidine is combined with Lithium.Approved
LobeglitazoneThe serum concentration of Tizanidine can be increased when it is combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Tizanidine is combined with Lofentanil.Illicit
LofepramineLofepramine may decrease the antihypertensive activities of Tizanidine.Experimental
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Tizanidine.Approved, Investigational
LomefloxacinThe serum concentration of Tizanidine can be increased when it is combined with Lomefloxacin.Approved, Investigational
LopinavirTizanidine may increase the QTc-prolonging activities of Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tizanidine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tizanidine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Lormetazepam.Approved
LorpiprazoleThe therapeutic efficacy of Tizanidine can be increased when used in combination with Lorpiprazole.Approved
LosartanThe serum concentration of Tizanidine can be increased when it is combined with Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tizanidine.Approved
LucinactantTizanidine may increase the bradycardic activities of Lucinactant.Approved, Investigational
LumefantrineTizanidine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tizanidine.Approved, Investigational
Magnesium SulfateThe therapeutic efficacy of Tizanidine can be increased when used in combination with Magnesium Sulfate.Approved, Investigational, Vet Approved
ManidipineThe serum concentration of Tizanidine can be increased when it is combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Tizanidine is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tizanidine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Tizanidine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Melperone.Approved, Investigational
MepindololTizanidine may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tizanidine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Mesoridazine.Approved, Investigational
MestranolThe serum concentration of Tizanidine can be increased when it is combined with Mestranol.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tizanidine.Approved
MethadoneTizanidine may increase the QTc-prolonging activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Tizanidine can be increased when it is combined with Methimazole.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tizanidine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tizanidine.Approved
MethotrimeprazineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tizanidine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methylecgonine.Experimental
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Tizanidine.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methylphenobarbital.Approved
MetipranololThe risk or severity of adverse effects can be increased when Tizanidine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Tizanidine.Approved
MetoprololTizanidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetyrosineTizanidine may increase the sedative activities of Metyrosine.Approved
MexiletineThe serum concentration of Tizanidine can be increased when it is combined with Mexiletine.Approved, Investigational
MianserinThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Mianserin.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tizanidine.Approved, Illicit
MidostaurinThe serum concentration of Tizanidine can be increased when it is combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Tizanidine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Tizanidine.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Tizanidine.Approved, Investigational
MirtazapineMirtazapine may decrease the antihypertensive activities of Tizanidine.Approved
MoclobemideThe serum concentration of Tizanidine can be increased when it is combined with Moclobemide.Approved, Investigational
MoexiprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tizanidine.Approved, Investigational
MoxifloxacinTizanidine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Tizanidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved, Investigational
NadololTizanidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tizanidine.Approved
NebivololTizanidine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Tizanidine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Tizanidine can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nesiritide.Approved, Investigational
NevirapineThe serum concentration of Tizanidine can be increased when it is combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Tizanidine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Tizanidine.Approved, Investigational
NifedipineThe serum concentration of Tizanidine can be increased when it is combined with Nifedipine.Approved
NilotinibTizanidine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Tizanidine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Tizanidine.Approved, Investigational
NisoldipineThe serum concentration of Tizanidine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tizanidine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Tizanidine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tizanidine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Tizanidine.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tizanidine.Approved, Vet Approved
NorfloxacinThe serum concentration of Tizanidine can be increased when it is combined with Norfloxacin.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Tizanidine.Approved
Obeticholic acidThe serum concentration of Tizanidine can be increased when it is combined with Obeticholic acid.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tizanidine.Approved, Investigational
OctreotideOctreotide may increase the bradycardic activities of Tizanidine.Approved, Investigational
OfloxacinTizanidine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Tizanidine can be increased when it is combined with Olanzapine.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tizanidine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Olopatadine.Approved
OmapatrilatThe risk or severity of hypotension can be increased when Tizanidine is combined with Omapatrilat.Investigational
OmeprazoleThe serum concentration of Tizanidine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Tizanidine can be increased when it is combined with Ondansetron.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Tizanidine.Investigational
OpiumThe risk or severity of adverse effects can be increased when Tizanidine is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Tizanidine can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineThe serum concentration of Tizanidine can be increased when it is combined with Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Tizanidine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Tizanidine can be decreased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tizanidine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Oxethazaine.Approved, Investigational
OxprenololTizanidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tizanidine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tizanidine.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tizanidine.Approved, Vet Approved
PaliperidoneTizanidine may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatTizanidine may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Papaverine.Approved, Investigational
ParaldehydeTizanidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe serum concentration of Tizanidine can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideTizanidine may increase the bradycardic activities of Pasireotide.Approved
PazopanibTizanidine may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2aThe serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololTizanidine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Penfluridol.Experimental
PentamidineTizanidine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tizanidine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tizanidine.Approved, Investigational, Vet Approved
PentoxifyllineThe serum concentration of Tizanidine can be increased when it is combined with Pentoxifylline.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
PerazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Perazine.Approved, Investigational
PerflutrenTizanidine may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Tizanidine is combined with Perospirone.Approved
PerphenazineThe serum concentration of Tizanidine can be increased when it is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tizanidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Tizanidine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Tizanidine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tizanidine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tizanidine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Phenoxyethanol.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Tizanidine.Approved
Phenylbutyric acidThe serum concentration of Tizanidine can be increased when it is combined with Phenylbutyric acid.Approved, Investigational
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tizanidine.Approved, Vet Approved
PibrentasvirThe serum concentration of Tizanidine can be increased when it is combined with Pibrentasvir.Approved, Investigational
PimozideTizanidine may increase the QTc-prolonging activities of Pimozide.Approved
PindololTizanidine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tizanidine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pizotifen.Approved
Platelet Activating FactorTizanidine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pomalidomide.Approved
Poractant alfaTizanidine may increase the bradycardic activities of Poractant alfa.Approved
PractololTizanidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleTizanidine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may decrease the vasoconstricting activities of Tizanidine.Approved
PregabalinThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Prilocaine.Approved
PrimaquineTizanidine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Primidone.Approved, Vet Approved
ProcainamideTizanidine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tizanidine.Approved, Vet Approved
PromazineTizanidine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Tizanidine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Tizanidine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Proparacaine.Approved, Vet Approved
PropofolThe serum concentration of Tizanidine can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Propoxycaine.Approved
PropranololThe serum concentration of Tizanidine can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Tizanidine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Tizanidine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tizanidine.Approved, Illicit
QuetiapineTizanidine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Quinapril.Approved, Investigational
QuinidineTizanidine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineTizanidine may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Ramipril.Approved
RanitidineThe serum concentration of Tizanidine can be increased when it is combined with Ranitidine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tizanidine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tizanidine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Remoxipride.Approved, Withdrawn
RescinnamineThe risk or severity of hypotension can be increased when Tizanidine is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tizanidine.Approved, Investigational
RheinThe serum concentration of Tizanidine can be increased when it is combined with Rhein.Experimental
RiociguatThe risk or severity of adverse effects can be increased when Tizanidine is combined with Riociguat.Approved
RisperidoneTizanidine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ritanserin.Investigational
RivastigmineTizanidine may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Romifidine.Vet Approved
RopiniroleThe serum concentration of Tizanidine can be increased when it is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tizanidine.Approved
RotigotineTizanidine may increase the sedative activities of Rotigotine.Approved
RucaparibThe serum concentration of Tizanidine can be increased when it is combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tizanidine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Tizanidine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tizanidine.Approved
SaquinavirTizanidine may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tizanidine.Approved, Vet Approved
SelegilineThe serum concentration of Tizanidine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Tizanidine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Tizanidine can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tizanidine.Approved, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Tizanidine.Approved
SimeprevirThe serum concentration of Tizanidine can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Tizanidine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
SotalolTizanidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpiraprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Spirapril.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Tizanidine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Tizanidine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tizanidine.Approved, Investigational
SulconazoleThe serum concentration of Tizanidine can be increased when it is combined with Sulconazole.Approved
SulfisoxazoleTizanidine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Sultopride.Experimental
SuvorexantTizanidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Tizanidine can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
TalinololTizanidine may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TamsulosinTamsulosin may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tasimelteon.Approved, Investigational
TelavancinTizanidine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTizanidine may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Tizanidine is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tizanidine.Approved, Investigational
TemocaprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Temocapril.Experimental, Investigational
Tenofovir disoproxilThe serum concentration of Tizanidine can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TerazosinTerazosin may decrease the vasoconstricting activities of Tizanidine.Approved
TeriflunomideThe serum concentration of Tizanidine can be decreased when it is combined with Teriflunomide.Approved
TertatololTizanidine may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TetrabenazineTizanidine may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tetrodotoxin.Investigational
ThalidomideTizanidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Tizanidine can be increased when it is combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Tizanidine can be increased when it is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tizanidine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tiagabine.Approved, Investigational
TianeptineTianeptine may decrease the antihypertensive activities of Tizanidine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tiapride.Approved, Investigational
TiclopidineThe serum concentration of Tizanidine can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tilidine.Experimental
TimololTizanidine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TioconazoleThe serum concentration of Tizanidine can be increased when it is combined with Tioconazole.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Tizanidine.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Tizanidine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tizanidine.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tizanidine.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Tizanidine.Approved
ToremifeneTizanidine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tizanidine.Approved, Investigational
TrandolaprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tizanidine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Tizanidine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Tizanidine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tizanidine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tizanidine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Tizanidine.Experimental
TrimipramineTrimipramine may decrease the antihypertensive activities of Tizanidine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tizanidine.Approved
UrapidilUrapidil may decrease the vasoconstricting activities of Tizanidine.Investigational
ValaciclovirThe serum concentration of Tizanidine can be increased when it is combined with Valaciclovir.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Tizanidine is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tizanidine.Approved, Investigational
VandetanibTizanidine may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe serum concentration of Tizanidine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Tizanidine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Veralipride.Experimental
VerapamilThe serum concentration of Tizanidine can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Tizanidine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Tizanidine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Xylazine.Vet Approved
ZafirlukastThe serum concentration of Tizanidine can be increased when it is combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tizanidine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ziconotide.Approved
ZileutonThe serum concentration of Tizanidine can be increased when it is combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Zimelidine.Withdrawn
ZiprasidoneTizanidine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZofenoprilThe risk or severity of hypotension can be increased when Tizanidine is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Zolazepam.Vet Approved
ZolpidemTizanidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tizanidine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Zotepine.Approved, Investigational
ZucapsaicinThe serum concentration of Tizanidine can be increased when it is combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolTizanidine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Pavel Hradil, Lubomir Kvapil, Martin Grepl, Jan Novotny, "METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE." U.S. Patent US20110263863, issued October 27, 2011.

US20110263863
General References
Not Available
External Links
Human Metabolome Database
HMDB0060964
KEGG Compound
C07452
PubChem Compound
5487
PubChem Substance
46505373
ChemSpider
5287
BindingDB
50240671
ChEBI
63629
ChEMBL
CHEMBL1079
Therapeutic Targets Database
DAP000234
PharmGKB
PA451701
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Tizanidine
ATC Codes
M03BX02 — Tizanidine
AHFS Codes
  • 12:20.04 — Centrally Acting Skeletal Muscle Relaxants
FDA label
Download (145 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedOtherMalignant Melanoma, Neoplasms1
1CompletedTreatmentHealthy Volunteers2
1TerminatedTreatmentSpasticity Due to Cerebral Palsy1
1, 2CompletedTreatmentMuscle Spasticity1
2CompletedTreatmentSpasticity1
2WithdrawnTreatmentAcute Muscle Pain1
3CompletedTreatmentDisseminated Sclerosis / Muscle Spasticity / Spinal Cord Injuries (SCI) / Strokes1
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentVertebrogenic Radiculopathy L5, S11
4CompletedTreatmentThyroidectomy1
4CompletedTreatmentUnilateral Inguinal Hernia1
4CompletedTreatmentUpper Limb Spasticity1
4RecruitingTreatmentLow Back Pain (LBP)1
Not AvailableCompletedNot AvailableArthritis / Gout Acute / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis1

Pharmacoeconomics

Manufacturers
  • Acorda therapeutics inc
  • Actavis elizabeth llc
  • Actavis totowa llc
  • Alphapharm party ltd
  • Apotex inc
  • Barr laboratories inc
  • Caraco pharmaceutical laboratories ltd
  • Corepharma llc
  • Dr reddys laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Kit
TabletOral2 mg/1
TabletOral2 mg
TabletOral4 mg/1
TabletOral4 mg
Capsule, gelatin coatedOral2 mg/1
Capsule, gelatin coatedOral4 mg/1
Capsule, gelatin coatedOral6 mg/1
CapsuleOral2 mg/1
CapsuleOral4 mg/1
CapsuleOral6 mg/1
Prices
Unit descriptionCostUnit
Zanaflex 6 mg capsule4.79USD capsule
Zanaflex 4 mg capsule3.2USD capsule
Zanaflex 2 mg capsule2.52USD capsule
Zanaflex 4 mg tablet2.29USD tablet
Tizanidine hcl 4 mg tablet1.49USD tablet
Zanaflex 2 mg tablet1.42USD tablet
Tizanidine hcl 2 mg tablet1.25USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6455557No2001-11-282021-11-28Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP1.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.133 mg/mLALOGPS
logP1.6ALOGPS
logP2.02ChemAxon
logS-3.3ALOGPS
pKa (Strongest Basic)7.49ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.2 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity64.77 m3·mol-1ChemAxon
Polarizability23.97 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8592
Caco-2 permeable+0.5323
P-glycoprotein substrateSubstrate0.6545
P-glycoprotein inhibitor INon-inhibitor0.8365
P-glycoprotein inhibitor IINon-inhibitor0.7953
Renal organic cation transporterInhibitor0.6577
CYP450 2C9 substrateNon-substrate0.7953
CYP450 2D6 substrateNon-substrate0.8018
CYP450 3A4 substrateNon-substrate0.5795
CYP450 1A2 substrateNon-inhibitor0.5248
CYP450 2C9 inhibitorNon-inhibitor0.7117
CYP450 2D6 inhibitorNon-inhibitor0.7867
CYP450 2C19 inhibitorNon-inhibitor0.6353
CYP450 3A4 inhibitorNon-inhibitor0.781
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.6538
CarcinogenicityNon-carcinogens0.8915
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6573 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6935
hERG inhibition (predictor II)Non-inhibitor0.8907
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0udi-5490000000-5ee0610f321160b63c82
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzothiadiazoles. These are heterocyclic aromatic compounds containing a benzene ring fused to a thiadiazole ring. Thiadiazole is a five-membered aromatic heterocycle made up of one sulfur atom and two nitrogen atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiadiazoles
Sub Class
Not Available
Direct Parent
Benzothiadiazoles
Alternative Parents
Benzenoids / Aryl chlorides / Thiadiazoles / Imidazolines / Heteroaromatic compounds / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds
show 2 more
Substituents
2,1,3-benzothiadiazole / Aryl chloride / Aryl halide / Benzenoid / Azole / Heteroaromatic compound / 2-imidazoline / Thiadiazole / Guanidine / Propargyl-type 1,3-dipolar organic compound
show 10 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
imidazoles, benzothiadiazole (CHEBI:63629)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702. [PubMed:8930173]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702. [PubMed:8930173]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702. [PubMed:8930173]
Details
4. Nischarin
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Agonist
General Function
Phosphatidylinositol binding
Specific Function
Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-si...
Gene Name
NISCH
Uniprot ID
Q9Y2I1
Uniprot Name
Nischarin
Molecular Weight
166627.105 Da
References
  1. Rolon PA: Myxoglobulosis of the appendix. Int Surg. 1977 Jun-Jul;62(6-7):355-6. [PubMed:893017]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Shellenberger MK, Groves L, Shah J, Novack GD: A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state. Drug Metab Dispos. 1999 Feb;27(2):201-4. [PubMed:9929503]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on February 13, 2018 09:38